Alnylam Pharmaceuticals, Inc. ( ALNY - Free Report ) incurred a loss of $1.62 per share in the first quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of $1.89 per share. The loss includes stock-based compensation expenses and unrealized gains on equity securities. Excluding these items, adjusted loss was $1.52 per share, wider than adjusted loss of $1.42 in the year-ago quarter.